Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Akebia Therapeutics, Inc. (AKBA) had Normalized Pre-Tax Income of $-8.84M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$49.13M |
|
$-8.91M |
|
$10.42M |
|
$38.70M |
|
$55.45M |
|
$-6.33M |
|
$-2.51M |
|
$-8.84M |
|
|
Normalized Pre-Tax Income |
$-8.84M |
$-8.91M |
|
$-8.91M |
|
$-8.91M |
|
$-8.91M |
|
$-6.33M |
|
$-5.74M |
|
269.60M |
|
269.60M |
|
$-0.03 |
|
$-0.03 |
|
| Balance Sheet Financials | |
$229.55M |
|
$1.51M |
|
$120.11M |
|
$349.66M |
|
$160.87M |
|
$24.75M |
|
$163.78M |
|
$324.64M |
|
$25.02M |
|
$-34.03M |
|
$25.02M |
|
271.74M |
|
| Cash Flow Statement Financials | |
$-17.68M |
|
$-4.14M |
|
$-7.46M |
|
$186.54M |
|
$157.26M |
|
$-29.29M |
|
$6.89M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.43 |
|
-- |
|
-- |
|
0.50 |
|
1.98 |
|
78.78% |
|
-12.88% |
|
-12.88% |
|
-- |
|
-17.99% |
|
-18.13% |
|
$-18.82M |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
0.80 |
|
0.92 |
|
98.02 |
|
-35.61% |
|
26.18% |
|
-2.55% |
|
-17.90% |
|
$0.09 |
|
$-0.07 |
|
$-0.07 |
|